Skip to content
OpenCapital
Get started

Replimune Group REPL Lease Liability Payments - 2021

Lease Liability Payments - 2021 at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's lease liability payments - 2021.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's lease liability payments - 2021?
Replimune Group (REPL) reported lease liability payments - 2021 of $2.88M in Q4 2025.
How has Replimune Group's lease liability payments - 2021 changed year-over-year?
Replimune Group's lease liability payments - 2021 increased by 3.0% year-over-year, from $2.8M to $2.88M.
What does lease liability payments - 2021 mean?
This metric captures the total contractual cash payments due for operating and finance leases specifically during the 2021 fiscal period. It serves as a historical or forward-looking benchmark for lease-related cash outflows. It is used by analysts to model the company's fixed cost structure and cash flow requirements.